The role of immunotherapy in the management of patients with malignant melanoma

James E Goodnight Jr, Donald L. Morton

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Immunotherapy using a variety of agents may be beneficial in controlling accessible cutaneous melanoma metastases and may have potential for limiting the growth of systemic disease when used in the adjuvant setting. Approximately 20% of patients with metastases limited to the skin can be brought into complete remission with local, intralesional BCG immunotherapy. Dinitrochlorobenzene (DNCB), vaccinia virus, C. parvum, and transfer factor have also been tested for activity in local immunotherapy. BCG, DNCB, and vaccinia virus appear to be the most effective. Adjuvant immunotherapy has shown some promise, particularly with regard to improvement in survival. In a study of adjuvant immunotherapy with BCG in patients with stage II disease, recurrence rates were similar, but of those patients who developed recurrences, those who received BCG lived significantly longer. Immunotherapy, used either alone or in combination with chemotherapeutic agents, has shown little or no activity in the treatment of metastatic malignant melanoma.

Original languageEnglish (US)
Pages (from-to)309-319
Number of pages11
JournalWorld Journal of Surgery
Volume3
Issue number3
DOIs
StatePublished - May 1979

Fingerprint

Immunotherapy
Melanoma
Mycobacterium bovis
Dinitrochlorobenzene
Vaccinia virus
Neoplasm Metastasis
Transfer Factor
Recurrence
Skin
Survival
Growth

ASJC Scopus subject areas

  • Surgery

Cite this

The role of immunotherapy in the management of patients with malignant melanoma. / Goodnight Jr, James E; Morton, Donald L.

In: World Journal of Surgery, Vol. 3, No. 3, 05.1979, p. 309-319.

Research output: Contribution to journalArticle

@article{600eddce114b4750a109c38c7e817031,
title = "The role of immunotherapy in the management of patients with malignant melanoma",
abstract = "Immunotherapy using a variety of agents may be beneficial in controlling accessible cutaneous melanoma metastases and may have potential for limiting the growth of systemic disease when used in the adjuvant setting. Approximately 20{\%} of patients with metastases limited to the skin can be brought into complete remission with local, intralesional BCG immunotherapy. Dinitrochlorobenzene (DNCB), vaccinia virus, C. parvum, and transfer factor have also been tested for activity in local immunotherapy. BCG, DNCB, and vaccinia virus appear to be the most effective. Adjuvant immunotherapy has shown some promise, particularly with regard to improvement in survival. In a study of adjuvant immunotherapy with BCG in patients with stage II disease, recurrence rates were similar, but of those patients who developed recurrences, those who received BCG lived significantly longer. Immunotherapy, used either alone or in combination with chemotherapeutic agents, has shown little or no activity in the treatment of metastatic malignant melanoma.",
author = "{Goodnight Jr}, {James E} and Morton, {Donald L.}",
year = "1979",
month = "5",
doi = "10.1007/BF01556582",
language = "English (US)",
volume = "3",
pages = "309--319",
journal = "Presentations from the 9th Annual Electric Utilities Environmental Conference",
issn = "0364-2313",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - The role of immunotherapy in the management of patients with malignant melanoma

AU - Goodnight Jr, James E

AU - Morton, Donald L.

PY - 1979/5

Y1 - 1979/5

N2 - Immunotherapy using a variety of agents may be beneficial in controlling accessible cutaneous melanoma metastases and may have potential for limiting the growth of systemic disease when used in the adjuvant setting. Approximately 20% of patients with metastases limited to the skin can be brought into complete remission with local, intralesional BCG immunotherapy. Dinitrochlorobenzene (DNCB), vaccinia virus, C. parvum, and transfer factor have also been tested for activity in local immunotherapy. BCG, DNCB, and vaccinia virus appear to be the most effective. Adjuvant immunotherapy has shown some promise, particularly with regard to improvement in survival. In a study of adjuvant immunotherapy with BCG in patients with stage II disease, recurrence rates were similar, but of those patients who developed recurrences, those who received BCG lived significantly longer. Immunotherapy, used either alone or in combination with chemotherapeutic agents, has shown little or no activity in the treatment of metastatic malignant melanoma.

AB - Immunotherapy using a variety of agents may be beneficial in controlling accessible cutaneous melanoma metastases and may have potential for limiting the growth of systemic disease when used in the adjuvant setting. Approximately 20% of patients with metastases limited to the skin can be brought into complete remission with local, intralesional BCG immunotherapy. Dinitrochlorobenzene (DNCB), vaccinia virus, C. parvum, and transfer factor have also been tested for activity in local immunotherapy. BCG, DNCB, and vaccinia virus appear to be the most effective. Adjuvant immunotherapy has shown some promise, particularly with regard to improvement in survival. In a study of adjuvant immunotherapy with BCG in patients with stage II disease, recurrence rates were similar, but of those patients who developed recurrences, those who received BCG lived significantly longer. Immunotherapy, used either alone or in combination with chemotherapeutic agents, has shown little or no activity in the treatment of metastatic malignant melanoma.

UR - http://www.scopus.com/inward/record.url?scp=0018777475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018777475&partnerID=8YFLogxK

U2 - 10.1007/BF01556582

DO - 10.1007/BF01556582

M3 - Article

C2 - 382645

AN - SCOPUS:0018777475

VL - 3

SP - 309

EP - 319

JO - Presentations from the 9th Annual Electric Utilities Environmental Conference

JF - Presentations from the 9th Annual Electric Utilities Environmental Conference

SN - 0364-2313

IS - 3

ER -